VXA-NVV-105

VXA-NVV-105 is an investigational **oral adenovirus serotype 5 vectored norovirus vaccine** being developed by Vaxart for prevention of norovirus infection and norovirus gastroenteritis. Based on the provided trial and program context, it is a bivalent vaccine candidate composed of monovalent oral Ad5-based components directed against **GI.1 Norwalk virus** and **GII.4 norovirus**, with the vector encoding the viral **VP1 capsid protein** antigen; at least the GI.1 component is described as an E1/E3-deleted, replication-defective recombinant Ad5 construct formulated with a **double-stranded RNA adjuvant** and delivered as an oral tablet. Its mechanism is to present norovirus capsid antigen to mucosal and systemic immune compartments after oral administration, inducing protective immune responses intended to prevent symptomatic norovirus disease.

Brand names

VXA-G1.1-NN + VXA-GII.4-NS

Other names

oral norovirus bivalent vaccineGI.1/GII.4 oral pill bivalent norovirus vaccinebivalent norovirus vaccine tablet